12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Solanezumab: Phase III data

Data from the 18-month, double-blind, international Phase III EXPEDITION1 and EXPEDITION2 trials in over 2,050 patients with mild to moderate AD combined showed that 400 mg IV solanezumab given every 4 weeks missed the primary endpoints vs. placebo. Specifically, data from EXPEDITION1 showed that solanezumab missed the co-primary endpoints of improving cognitive (ADAS-Cog11) and functional (ADCS-ADL) scores from baseline to week 80 vs. placebo. A pre-specified secondary subgroup analysis showed that solanezumab did significantly improve ADAS-Cog11 scores vs. placebo in patients with mild...

Read the full 394 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >